Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Aquestive Therapeutics, Inc. (AQST) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Other Events  Interactive Data
Docs: "Aquestive Therapeutics Provides Business Update"
10/02/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
10/02/2023 EFFECT Form EFFECT - Notice of Effectiveness:
08/11/2023 8-K Investor presentation
Docs: "of the Private Securities Litigation Reform Act of 1995. Words"
08/09/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/07/2023 8-K Investor presentation, Quarterly results
Docs: "Exhibit 99.1 Aquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update"
08/07/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/02/2023 8-K Quarterly results
07/27/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "Aquestive Therapeutics Announces Positive Topline Pharmacokinetic Data for Anaphylm™ Sublingual Film"
06/29/2023 8-K Investor presentation
Docs: "Aquestive Therapeutics Corporate Presentation",
"Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment"
05/31/2023 8-K Investor presentation
Docs: "Aquestive Therapeutics Reports Positive Results from Latest Clinical Studies Evaluating Pharmacokinetic and Pharmacodynamic Performance of Anaphylm"
05/02/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/02/2023 8-K Quarterly results
05/02/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/18/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
04/13/2023 8-K Quarterly results
03/31/2023 10-K Annual Report for the period ended December 31, 2022
03/07/2023 8-K Investor presentation
03/07/2023 8-K Investor presentation, Quarterly results
Docs: "Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives",
"2022 14.7 17.7 18.6 27.3 0 5 10 15 20 25 30"
03/06/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
02/07/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "AMENDED AND RESTATED BYLAWS OF AQUESTIVE THERAPEUTICS, INC."
01/18/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
01/03/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
12/22/2022 8-K Quarterly results
12/20/2022 8-K Quarterly results
11/07/2022 8-K Other Events  Interactive Data
11/02/2022 8-K Quarterly results
11/01/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/01/2022 8-K Quarterly results
10/27/2022 8-K Quarterly results
10/24/2022 8-K Quarterly results
10/11/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aquestive Therapeutics Receives Positive FDA Written Response for AQST-109 Epinephrine Sublingual Film"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy